Compare BridgeBio Pharma Inc (BBIO) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Goldman Sachs Group Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Goldman Sachs Group Inc trades at $1,034.44 (market cap $301.22B). The key difference: Goldman Sachs Group Inc is far larger — about 18.1× BridgeBio Pharma Inc's market cap, and Goldman Sachs Group Inc pays a 1.93% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GS | |
|---|---|---|
Market Cap | $16.61B | $301.22B |
Sector | Health | Financials |
52-Week High | $90.17 | $1.15K |
52-Week Low | $47.29 | $715.95 |
Enterprise Value | $18.16B | — |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Goldman Sachs (GS) trades at $1,034.41, down 0.5% on the day, with a neutral technical signal. The company shows strong fundamental momentum with three consecutive quarterly EPS beats and revenue growth accelerating to $58.3B in 2025. Analyst consensus is mixed with 40% buy ratings but a $1,160 price target suggesting 12% upside potential. Recent news highlights Goldman's leadership role in major upcoming IPOs including Anthropic, SpaceX, and OpenAI.
The outlook remains positive given Goldman's positioning in the upcoming AI IPO wave and strong investment banking pipeline. Key risks include volatile cash flow patterns with negative operating cash flow in recent periods and market sensitivity to interest rate changes. The stock appears reasonably valued at 16x P/E with 31.7% net margins supporting further upside if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
